CP-39,332
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
This is the current revision of this page, as edited by JJMC89 bot III (talk | contribs) at 19:55, 20 December 2023 (Moving Category:Pfizer brands to Category:Drugs developed by Pfizer per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands). The present address (URL) is a permanent link to this version.
Revision as of 19:55, 20 December 2023 by JJMC89 bot III (talk | contribs) (Moving Category:Pfizer brands to Category:Drugs developed by Pfizer per Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands)
(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)
Chemical compound
Pharmaceutical compound
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H19N |
Molar mass | 237.346 g·mol−1 |
3D model (JSmol) | |
|
CP-39,332 is a drug which acts as a serotonin-norepinephrine reuptake inhibitor.[1] Tametraline (1R,4S-), CP-24,442 (1S,4R-), CP-22,185 (cis-), and CP-22,186 (trans-) are stereoisomers of the compound and show varying effects on monoamine reuptake.[1] None of them were ever marketed.
See also
[edit]References
[edit]
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
|
This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- All stub articles